PD01-07 MEDICAL-GRADE MANUKA HONEY (MEDIHONEY®) POTENTIAL EFFICACY IN THE MANAGEMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME: AN IN VITRO MODEL OF UROTHELIAL INFLAMMATION

Abstract

You have accessJournal of UrologyInfections/Inflammation/Cystic Disease of the Genitourinary Tract: Interstitial Cystitis (PD01)1 Sep 2021PD01-07 MEDICAL-GRADE MANUKA HONEY (MEDIHONEY®) POTENTIAL EFFICACY IN THE MANAGEMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME: AN IN VITRO MODEL OF UROTHELIAL INFLAMMATION Muhammadbakhoree Yusuh, Laurie Lau, Omar Abdelwahab, Kamaluddeen Garba, Prapussara Sirikhansaeng, Brian Birch, and Bashir Lwaleed Muhammadbakhoree YusuhMuhammadbakhoree Yusuh More articles by this author , Laurie LauLaurie Lau More articles by this author , Omar AbdelwahabOmar Abdelwahab More articles by this author , Kamaluddeen GarbaKamaluddeen Garba More articles by this author , Prapussara SirikhansaengPrapussara Sirikhansaeng More articles by this author , Brian BirchBrian Birch More articles by this author , and Bashir LwaleedBashir Lwaleed More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001965.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) refers to “spontaneous” conditions of varied aetiologies and defined as chronic pelvic pain, pressure or discomfort, urge to void, frequency and nocturia. It is characterised by bladder wall inflammation, defective bladder urothelium, and increased levels of the pro-inflammatory cytokine TNF-α in the bladder tissue. The release of TNF-α by the urothelial cells further aggravates the inflammatory response in patients with IC/BPS. Commonly, Medical grade Manuka honey (Medihoney® (MH)) possesses strong pro-angiogenic and anti-microbial properties. Our recent findings have highlighted its anti-inflammatory effects through inhibition of induced mast cell degranulation. In addition, we demonstrated that MH is well tolerated by the rat urothelial cells where it was cytoprotective against acid damage. In the present study, we investigated the cytotoxic and anti-inflammatory effects of MH using an in vitro model of primary human urothelial cells (HUCs). METHODS: Cytotoxic effect of various concentrations of MH on HUCs at 1, 24, 48, and 72 hours was evaluated using MTT assay. In addition, the release of the pro-inflammatory cytokines IL-8 and IL-6 in the HUCs after 24-hour incubation with TNF-α (10 ng/ml) with/without pre-treatment with 4% MH was assessed using ELISA assays. RESULTS: One hour incubation with MH (2%, 4%, 6% and 8% w/v) did not induce significant cytotoxic effects on the HUCs. However, when the cells were incubated with MH for a longer periods, we observed an incremental cytotoxic effect, especially at 6% and 8% (Figure 1). In addition, 4% MH significantly decreased the TNF-α induced release of IL-6 and IL-8 in the urothelial cells (Figure 2). CONCLUSIONS: Our results indicate that MH is not cytotoxic to urothelial cells and has potential use as an intravesical therapeutic agent for the management for bladder inflammatory conditions such as IC/BPS. Source of Funding: N/A © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e33-e33 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Muhammadbakhoree Yusuh More articles by this author Laurie Lau More articles by this author Omar Abdelwahab More articles by this author Kamaluddeen Garba More articles by this author Prapussara Sirikhansaeng More articles by this author Brian Birch More articles by this author Bashir Lwaleed More articles by this author Expand All Advertisement Loading ...